Inspira Technologies Oxy B.H.N (Nasdaq:IINN) - Hisse Senedi Fiyatı, Haberler ve Analizler

IINN Stoklara Genel Bakış

Özel bir tıbbi cihaz şirketi olan Inspira Technologies Oxy B.H.N. Ltd. akut solunum yetmezliği tedavisi için tescilli yaşam destek teknolojisinin araştırılması, geliştirilmesi, üretimi ve pazarlanmasıyla ilgilenmektedir. Daha fazla detay

IINN temel anali̇z
Kar Tanesi Skoru
Değerleme	1/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	4/6
Temettüler	0/6

Risk Analizi

Geliri 1 milyon ABD dolarından az ( $0 )

Kazançlar son 5 yılda yılda 22.3% oranında azaldı

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

Son mali raporlar 6 aydan daha eskidir

+ 1 daha fazla risk

Inspira Technologies Oxy B.H.N. Ltd. Rakipler

Neuronetics

NasdaqGM:STIM

US$29.4m

Vaso

OTCPK:VASO

US$22.7m

Femasys

NasdaqCM:FEMY

US$25.2m

IRIDEX

NasdaqCM:IRIX

US$29.4m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Inspira Technologies Oxy B.H.N
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$1.38
52 Haftanın En Yüksek Seviyesi	US$2.49
52 Haftanın En Düşük Seviyesi	US$0.76
Beta	2.09
11 Aylık Değişim	2.22%
3 Aylık Değişim	23.21%
1 Yıllık Değişim	35.29%
33 Yıllık Değişim	-54.15%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-70.95%

Son Haberler & Güncellemeler

Recent updates

Inspira Technologies reports 1H results

Aug 11

Inspira stock soars 71% on developing non-invasive optical blood sensor Hyla

Jul 06

Hissedar Getirileri

	IINN	US Medical Equipment	US Pazar
7D	7.8%	1.2%	2.0%
1Y	35.3%	22.6%	32.4%

Getiri vs. Endüstri: IINN geçen yıl % 22.6 oranında getiri sağlayan US Medical Equipment sektörünü aştı.

Getiri vs Piyasa: IINN geçen yıl % 32.4 oranında getiri sağlayan US Piyasasını aştı.

Fiyat Oynaklığı

Is IINN's price volatile compared to industry and market?
IINN volatility
IINN Average Weekly Movement	6.5%
Medical Equipment Industry Average Movement	8.0%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.9%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: IINN son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: IINN 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 12% dan 6% a düştü.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2018	40	Dagi Ben-Noon	inspira-technologies.com

Özel bir tıbbi cihaz şirketi olan Inspira Technologies Oxy B.H.N. Ltd. akut solunum yetmezliğinin tedavisi için tescilli yaşam destek teknolojisinin araştırılması, geliştirilmesi, üretimi ve pazarlanmasıyla ilgilenmektedir.

Inspira Technologies Oxy B.H.N. Ltd. Temel Bilgiler Özeti

Inspira Technologies Oxy B.H.N'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
IINN temel i̇stati̇sti̇kler
Piyasa değeri	US$25.16m
Kazançlar(TTM)	-US$11.29m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-2.3x

F/K Oranı

IINN aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
IINN gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$0
Brüt Kâr	US$0
Diğer Giderler	US$11.29m
Kazançlar	-US$11.29m

Son Raporlanan Kazançlar

Dec 31, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.61
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	0%

IINN uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

IINN Stoklara Genel Bakış

Risk Analizi

Inspira Technologies Oxy B.H.N. Ltd. Rakipler

NasdaqGM:STIM

US$29.4m

OTCPK:VASO

US$22.7m

NasdaqCM:FEMY

US$25.2m

NasdaqCM:IRIX

US$29.4m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Inspira Technologies Oxy B.H.N. Ltd., Annual General Meeting, Dec 30, 2024

New minor risk - Financial data availability

Inspira Technologies Oxy B.H.N. Ltd. Announces Development of New Disposable Kit with Built-In Performance Monitoring Mechanism

Inspira Secures Second U.S. Patent Approval for Orbiting Blood Oxygenation Delivery System

Independent Chairman of the Board notifies of intention to sell stock

Inspira Technologies OXY B.H.N. Ltd. Announces FDA Listing and Market Readiness of New Product

Recent updates

Inspira Technologies Oxy B.H.N. Ltd., Annual General Meeting, Dec 30, 2024

New minor risk - Financial data availability

Inspira Technologies Oxy B.H.N. Ltd. Announces Development of New Disposable Kit with Built-In Performance Monitoring Mechanism

Inspira Secures Second U.S. Patent Approval for Orbiting Blood Oxygenation Delivery System

Independent Chairman of the Board notifies of intention to sell stock

Inspira Technologies OXY B.H.N. Ltd. Announces FDA Listing and Market Readiness of New Product

Inspira Technologies OXY B.H.N. Introduces the INSPIRA Cardi-ART, Aiming to Provide Oxygen to the Brain During Cardiac Arrest

New major risk - Shareholder dilution

Inspira Technologies OXY B.H.N. Ltd. Receives Israeli Regulatory Approval for the INSPIRA ART100 System

Inspira™ Introduces Advanced Life Support Solutions to Key International Leaders at the Annual iECOs Conference in Israel

Inspira™ Introduces Advanced Life Support Solutions to Key International Leaders at the Annual iECOs Conference in Israel

Inspira™ Announces Start of Production of the Inspira™ Art100

Price target increased by 44% to US$13.00

Inspira™? and Ennocure In Vitro Study Results Show 100% Prevention of Bacterial Growth Causes Bloodstream Infections

Inspira™ Technologies Oxy B.H.N. Ltd. Announces Program to Pioneer the Applicable Use of the INSPIRA™ ART100 Device for an Artificial Womb

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Inspira Technologies OXY B.H.N. Ltd. Announces AMAR Regulatory Submission of the INSPIRA™ ART100, to Enter the Southeast Asia and South American Markets

Inspira Releases New Data Demonstrating Superiority of its Core Technology, Across Key Endpoints of HMSS Indicator

Inspira Technologies OXY B.H.N. Ltd. Introduces High-End Platform for Bio-Mimicking Blood parameters for Development and Testing of Core Technologies

Inspiratm Technologies OXY B.H.N. Ltd. Receives First Ever U.S. Patent Approval for an Orbiting Blood Oxygenation Delivery System

New minor risk - Share price stability

Inspira Technologies Oxy B.H.N. Ltd. Announces Plans to Launch and Target Single-Use Disposable Blood Oxygenation Kit for A New Disposable Perfusion Market Opportunity

Inspira Technologies Oxy B.H.N. Ltd. has completed a Follow-on Equity Offering in the amount of $3.88 million.

Inspira Technologies Oxy B.H.N. Ltd. has filed a Follow-on Equity Offering in the amount of $3.88 million.

Inspira Technologies Oxy B.H.N. Ltd. has filed a Follow-on Equity Offering in the amount of $3.88 million.

Inspira Technologies OXY BHN Ltd. Announces 95% Accuracy Results for HYLA™? Blood Sensor, Planning FDA Submission for Clearance in 2024

Inspira Technologies Oxy B.H.N. Ltd. Announces Appointment of Dan Gorfil to its Medical Advisory Board

Inspira Technologies Oxy B.H.N. Ltd., Annual General Meeting, Dec 27, 2023

Inspira Technologies Oxy B.H.N. Ltd. Announces Israeli Innovation Authority Grant for New VORTX Disposable Blood Oxygenation Technology

Inspira Technologies OXY BHN Ltd. Announces the Grant of an Additional Patent by the U.S. Patent and Trademark Office for its Respiratory Medical Device, the INSPIRAART500

Inspira Technologies Unveils the Inspira™ Art Line of Medical Devices At the World's Largest Extracorporeal Life Support Conference

Inspira™? Announces 510(k) FDA Submission of INSPIRA™? ART100 Towards Commercialization

Inspira Technologies Appoints Dr. Nir as Chief Medical Officer

Inspira Technologies Oxy B.H.N. Ltd. to Reveal the New ALICE Device at the World's Largest Extracorporeal Life Support Conference

Inspira™ Technologies OXY B.H.N. Ltd. Develops the VORTX™ Blood Oxygenator, a Unique Technology for Saturating Blood With Oxygen and Removing Carbon Dioxide

Inspira(TM) Technologies Receives Approval from Sheba Medical Center to Conduct Clinical Study of the HYLA(TM) Blood Sensor

Inspira Technologies Receives Patent by U.S. Patent Office for the INSPIRA ART System's Convertible Dual Lumen Cannula Device and Method of Use

Inspira Technologies Oxy B.H.N. Ltd. Begins Manufacturing of the ALICE™ CPB Device, ahead of planned 2023 FDA submission

Less than half of directors are independent

Inspira Technologies Oxy B.H.N. Ltd. Receives Patent by the Israeli Patent Office for Key Safety Component for the INSPIRATM ART System

Chairman of the Board notifies of intention to sell stock

Inspira Technologies Oxy B.H.N. Ltd., Annual General Meeting, Oct 18, 2022

Inspira™ Technologies Performed HYLA™ Blood Sensor In-Vivo Study, in Preparation of Planned Human Studies

Inspira Technologies Oxy B.H.N. Ltd. Announces Changes in Management

Inspira Technologies reports 1H results

Inspira™ Technologies Reveals Next Generation Liby™ ECMO

Inspira Technologies Develops A Non-Invasive Blood Sensor

Inspira stock soars 71% on developing non-invasive optical blood sensor Hyla

Chairman of the Board notifies of intention to sell stock

Less than half of directors are independent

Inspira Technologies Appoints Daniella Yeheskely-Hayon as the New Chief Technology Officer

Inspira Technologies Oxy B.H.N. Ltd. Lists a Component of its ART and ECLS Systems on the U.S. Food and Drug Administration Class I 510(K) Exempt List

Inspira Technologies Oxy B.H.N. Ltd. Files A Pct Patent Application for Its Flagship Art Device and Proprietary Method of Use to Minimize the Need for Mechanical Ventilation

Inspira Technologies Oxy B.H.N. Ltd. has completed an IPO in the amount of $16.029091 million.

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

Inspira Technologies Oxy B.H.N. Ltd. Temel Bilgiler Özeti

0.0x